3 / 15
Page 16
Volume 2
July 24-25, 2019 | Rome, Italy
World Hematology 2019 & Nursing Care 2019
July 24-25, 2019
Journal of Blood Disorders and Treatment
47
th
WORLD CONGRESS ON NURSING CARE
11
th
WORLD HEMATOLOGY AND ONCOLOGY CONGRESS
&
J Blood Disord Treat, Volume 2
Anlotinib is effective in the treatment of advanced carcinoma ex pleomorphic adenoma
of the submandibular gland
Shujie Song, Ping Sui, Dengjun Sun
Yantai Yuhuangding Hospital of Qingdao University, China
Background
: Carcinoma ex pleomorphic adenoma (CXPA), a very rare malignancy found mostly in the major salivary glands,
has no established standardized treatment.
Case presentation
: This report describes a 67-year-old male with advanced CXPA who was effectively treated by anlotinib.
Pleomorphic adenoma of the submandibular gland was first diagnosed in 1976 after a surgical resection of a mass underneath
the jaw. The patient underwent re-excision 3 years later due to a recurrent pleomorphic adenoma. CXPA was first diagnosed in
2016 after a surgical removal of the left submandibular mass. A lung nodule was found on a chest CT scan in January 2018.
Following a CT-guided lung biopsy that demonstrated findings consistent with pulmonary metastasis, the patient underwent local
therapy (microwave ablation and radioactive seed implantation) but suffered a recurrence of disease approximately 6 months
later. Anlotinib was administered orally at a dose of 12 mg daily on a 2 weeks on/1 week off schedule. A tumor assessment was
performed every 2 cycles. A partial response was observed after two cycles of treatment. The disease remains in continued partial
response after completion of his 10th cycle.
Conclusion
: This is the first report for anlotinib in treating CXPA. Further pre-clinical and clinical studies are needed to validate
the efficacy and safety of anlotinib in the treatment of CXPA.
Biography
Dengjun Sun is a professional oncologist and has his expertise in the diagnosis and treatment of malignant tumors. He owns normative
treatment philosophy and has rich clinical experience in the interventional and targeted therapy of liver cancer, lung cancer, breast
cancer and other solid tumors. He is one of the members of the World Society of Interventional Oncology (SIO) and an important
member of Interventional and Minimally Invasive therapy Committee of Chinese Medical Education Association. With extensive
research and rich clinical experience in cancer therapy, he has helped many advanced cancer patients in China.
sundengjun@sina.comFigure 1
(A)
Histology of primary carcinoma ex pleomorphic adenoma;
(B)
Immunohistochemistry showed that tumor cells were positive for CK8/18.
(C)
Immunohistochemistry showed that Ki 67 was 30–40%.
(D)
Histology of pulmonary
metastasis.
(E)
Immunohistochemistry showed that tumor cells were positive for
CK8/18.
(F)
Immunohistochemistry showed that Ki 67 was about 70%. (
A–F
) Original
magnification, ×100,(
A–C
: primary carcinoma ex pleomorphic adenoma of the
submandibular gland,
D–F
: pulmonary metastasis,
A
and
D
: hematoxylin-eosin).
Figure 2
Chest CT scans before and after anlotinib treatment. (
A
and
D
): Before
anlotinib treatment, two measurable tumor lesions were shown. (
B
and
E
) After two
cycles of anlotinib treatment, a Partial response was observed. (
C
and
F
) After six cycles
of anlotinib treatment, a continued partial response was observed. The white and black
arrowheads aim at two measurable tumor lesions, respectively. Response assessment was
based on RECIST guideline version 1.1